RS50262B - Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva - Google Patents

Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva

Info

Publication number
RS50262B
RS50262B YU14502A YUP14502A RS50262B RS 50262 B RS50262 B RS 50262B YU 14502 A YU14502 A YU 14502A YU P14502 A YUP14502 A YU P14502A RS 50262 B RS50262 B RS 50262B
Authority
RS
Serbia
Prior art keywords
drospirenone
administration
ethinylestradiol
contraceptive
pharmaceutical combination
Prior art date
Application number
YU14502A
Other languages
English (en)
Inventor
Wolfgang Heil
Ralph Lipp
Renate Heithecker
Jürgen Hilman
Original Assignee
Bayer Schering Pharma Aktiengesellschaft,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50262(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft, filed Critical Bayer Schering Pharma Aktiengesellschaft,
Publication of YU14502A publication Critical patent/YU14502A/sh
Publication of RS50262B publication Critical patent/RS50262B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmaceutska kompozicija koja sadrži, kao prvo aktivno sredstvo drospirenon u količini koja odgovara dnevnoj dozi, nakon davanja kompozicije, od oko 2 mg do 4 mg, i kao drugo aktivno sredstvo, etinilestradiol u količini koja odgovara dnevnoj dozi od oko 0,01 mg do 0,05 mg, zajedno sa jednim ili više farmaceutski prihvatljivih nosača ili inertnih punilaca, naznačena time, što se bar 70% navedenog drospirenona rastvori iz navedene kompozicije za 30 minuta, kako je to utvrđeno putem USP XXIII Paddle Method II upotrebom vode na 37°C kao medijuma rastvaranja i pri brzini mešanja od 50 obrtaja u minuti.
YU14502A 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva RS50262B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38627499A 1999-08-31 1999-08-31
EP99202826 1999-08-31

Publications (2)

Publication Number Publication Date
YU14502A YU14502A (sh) 2006-01-16
RS50262B true RS50262B (sr) 2009-07-15

Family

ID=26153359

Family Applications (3)

Application Number Title Priority Date Filing Date
YU14502A RS50262B (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
RS14502A RS50262B2 (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
RSP-2009/0134A RS20090134A (en) 1999-08-31 2000-08-31 Pharmaceutical combinattion of ethinylestradiol and drospinenone for use as a contraceptive

Family Applications After (2)

Application Number Title Priority Date Filing Date
RS14502A RS50262B2 (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
RSP-2009/0134A RS20090134A (en) 1999-08-31 2000-08-31 Pharmaceutical combinattion of ethinylestradiol and drospinenone for use as a contraceptive

Country Status (26)

Country Link
EP (4) EP1380301B1 (sr)
JP (2) JP4354667B2 (sr)
KR (2) KR100857344B1 (sr)
AT (3) ATE420648T1 (sr)
AU (4) AU780330B2 (sr)
BG (1) BG66114B1 (sr)
BR (1) BR0014159A (sr)
CY (3) CY1108990T1 (sr)
CZ (1) CZ300514B6 (sr)
DE (5) DE122009000007I2 (sr)
DK (3) DK1214076T3 (sr)
EE (1) EE05128B1 (sr)
ES (3) ES2211580T3 (sr)
HK (1) HK1047247B (sr)
HR (1) HRP20070188B1 (sr)
HU (1) HU227207B1 (sr)
IL (1) IL148339A0 (sr)
ME (2) MEP36008A (sr)
NO (1) NO326860B1 (sr)
NZ (1) NZ517845A (sr)
PL (1) PL199028B1 (sr)
PT (3) PT1598069E (sr)
RS (3) RS50262B (sr)
SI (3) SI1380301T1 (sr)
TW (1) TWI276436B (sr)
WO (1) WO2001015701A1 (sr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP36008A (hr) * 1999-08-31 2011-02-10 Bayer Schering Pharma Ag Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
DE60139907D1 (de) * 2000-01-18 2009-10-22 Bayer Schering Pharma Ag Pharmazeutische Zubereitung enthaltend Drospirenon
EP1353699B1 (en) * 2000-12-20 2012-02-01 Bayer Pharma Aktiengesellschaft Beta-cyclodextrin-drospirenone inclusion complexes
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
CN1649596A (zh) * 2002-04-26 2005-08-03 舍林股份公司 治疗接受激素替代疗法之妇女中的高血压的方法
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
NZ549792A (en) * 2004-03-10 2009-12-24 Bayer Schering Pharma Ag Compositions comprising drospirenone molecularly dispersed
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
AU2006228947A1 (en) * 2005-03-30 2006-10-05 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
EP1900359A1 (en) * 2006-09-16 2008-03-19 KAIROSmed GmbH Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception
EP2063870A2 (en) * 2006-09-16 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Oral modified release formulations
WO2008122439A2 (en) * 2007-04-05 2008-10-16 Bayer Schering Pharma Aktiengesellschaft Dr0spiren0ne/17beta-estradi0l regimen, pharmaceutical combination product and kit for performing this regimen
HUP0700826A3 (en) * 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2558063B1 (en) * 2010-04-15 2021-09-29 Bayer Intellectual Property GmbH Very low-dosed solid oral dosage forms for hrt
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IT202100008834A1 (it) 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
US20250186337A1 (en) * 2022-03-01 2025-06-12 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3051167C3 (de) * 1979-01-24 1994-11-24 Minnesota Mining & Mfg Fluorierte Alkohole
DE3051166C2 (en) 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3682130D1 (de) * 1985-07-15 1991-11-28 Japan Res Dev Corp Verfahren zur herstellung von ultrafeinen organischen verbindungen.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
RU2166936C2 (ru) * 1994-09-22 2001-05-20 Акцо Нобель Н.В. Способ получения дозировочных единиц путем мокрой грануляции
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DK0917466T3 (da) * 1996-07-26 2004-12-20 Wyeth Corp Oralt antikonceptionsmiddel
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
BR9710566A (pt) * 1996-07-26 1999-08-17 American Home Prod M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
MEP36008A (hr) * 1999-08-31 2011-02-10 Bayer Schering Pharma Ag Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva
DE60139907D1 (de) * 2000-01-18 2009-10-22 Bayer Schering Pharma Ag Pharmazeutische Zubereitung enthaltend Drospirenon

Also Published As

Publication number Publication date
AU2010226924A1 (en) 2010-10-28
NZ517845A (en) 2004-12-24
SI1214076T1 (en) 2004-06-30
EP1598069A2 (en) 2005-11-23
DK1598069T3 (da) 2009-07-06
HUP0202500A2 (en) 2002-10-28
ES2211580T3 (es) 2004-07-16
AU2005202046B2 (en) 2008-11-20
BR0014159A (pt) 2002-05-07
AU2005202046B9 (en) 2008-12-11
AU2009200247A1 (en) 2009-02-19
ES2325589T3 (es) 2009-09-09
CY2009015I2 (el) 2014-02-12
JP2003508441A (ja) 2003-03-04
KR20070067248A (ko) 2007-06-27
AU2005202046A1 (en) 2005-06-09
DK1214076T3 (da) 2004-02-23
HK1061968A1 (en) 2004-10-15
EP2044941A1 (en) 2009-04-08
EP1214076A1 (en) 2002-06-19
DK1380301T3 (da) 2009-04-20
TWI276436B (en) 2007-03-21
HK1047247A1 (en) 2003-02-14
DE60041421D1 (de) 2009-03-05
EP1380301B1 (en) 2009-01-14
NO20020801D0 (no) 2002-02-19
HK1082432A1 (en) 2006-06-09
ATE254464T1 (de) 2003-12-15
DE60006692D1 (de) 2003-12-24
SI1380301T1 (sl) 2009-06-30
PT1214076E (pt) 2004-04-30
DE122009000006I2 (de) 2012-03-22
EE05128B1 (et) 2009-02-16
CY1109252T1 (el) 2014-07-02
HRP20070188B1 (hr) 2015-06-19
BG66114B1 (bg) 2011-05-31
DE122009000007I2 (de) 2011-07-21
ATE420648T1 (de) 2009-01-15
DE122009000007I1 (de) 2009-05-07
JP2009143959A (ja) 2009-07-02
CZ300514B6 (cs) 2009-06-03
AU6589500A (en) 2001-03-26
HUP0202500A3 (en) 2004-04-28
ATE429231T1 (de) 2009-05-15
DE60006692T2 (de) 2004-09-23
DE60042089D1 (de) 2009-06-04
NO326860B1 (no) 2009-03-02
YU14502A (sh) 2006-01-16
SI1598069T1 (sl) 2009-10-31
CY2009015I1 (el) 2014-02-12
MEP36008A (hr) 2011-02-10
PL199028B1 (pl) 2008-08-29
CZ2002615A3 (cs) 2002-08-14
AU780330B2 (en) 2005-03-17
NO20020801L (no) 2002-04-26
PL354406A1 (pl) 2004-01-12
IL148339A0 (en) 2002-09-12
WO2001015701A1 (en) 2001-03-08
HK1047247B (en) 2004-07-23
RS50262B2 (sr) 2018-10-31
EP1598069A3 (en) 2006-04-05
RS20090134A (en) 2009-11-10
EP1598069B1 (en) 2009-04-22
DE122009000006I1 (de) 2009-05-07
EP1380301A1 (en) 2004-01-14
ES2319750T3 (es) 2009-05-12
KR100857344B1 (ko) 2008-09-05
AU2009200247B2 (en) 2010-07-01
JP4354667B2 (ja) 2009-10-28
KR20020040798A (ko) 2002-05-30
ME00329B (me) 2011-05-10
PT1380301E (pt) 2009-03-30
KR101019361B1 (ko) 2011-03-07
CY1108990T1 (el) 2014-02-12
PT1598069E (pt) 2009-07-20
EP1214076B1 (en) 2003-11-19
HU227207B1 (en) 2010-11-29
HRP20070188A2 (en) 2007-07-31
EE200200110A (et) 2003-06-16

Similar Documents

Publication Publication Date Title
RS50262B (sr) Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
RS52149B (sr) Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona
ES2558030T3 (es) Método anticonceptivo oral multifásico de ciclo prolongado
JP2015531400A5 (sr)
MX2007013137A (es) Regimen anticonceptivo con dosificacion de estrogeno ampliada.
BR9912466A (pt) Utilização de sulfamatos de estrogênio biogênicos na terapia de reposição hormonal
WO2006042021B1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
HRP20020258B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
RU2225714C2 (ru) Новый набор противозачаточных средств
RU2000125572A (ru) Новый набор противозачаточных средств
RS50849B (sr) Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu
AR025443A1 (es) Una composicion farmaceutica para ser usada como anticonceptivo.
FR2803521B1 (fr) Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
KR970009798A (ko) 포유동물에서의 유리 라디칼 손상을 감소시키기 위해 철 킬레이트화 화합물을 사용하는 방법
CO5770093A1 (es) Composiciones farmaceuticas solidas que comprenden una combinacion de drospirenona, etinilestradiol y un agente surfractante adecuado que presenta una homogeneidad de contenido y velocidad de disolucion asegurada para la droga no micronizada, rpocedi